Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compensatory Intercellular Mitochondrial Transfer Improves Bioenergetics in P301L Tau-Affected Neuronal Cells.

Cells·2026
Same author

Protocol for automated quantification of neuronal cells using the Agilent BioTek Cytation system and Gen5 neurite outgrowth module.

STAR protocols·2026
Same author

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression.

EMBO molecular medicine·2026
Same author

Estetrol Enhances Mitochondrial Bioenergetics and Neurite Outgrowth in Cellular Models of Alzheimer's Disease.

Cells·2026
Same author

Modeling the chondrocyte-derived osteoblasts formation process reveals its molecular signature and regulation network.

Bone research·2026
Same author

Cellular quiescence uncouples the proteome from the transcriptome in neural stem cells.

The EMBO journal·2026

Related Experiment Video

Updated: Jun 24, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

Fluorinated apelin-13 mediates neuroprotective effects in multiple sclerosis models.

Dafni Birmpili1, Imane Charmarké-Askar1, Caroline Spenlé1

  • 1Centre national de la Recherche Scientifique (CNRS) UMRS7242, Biotechnology and Cell Signaling, Therapeutic Peptides Team, Institut du Médicament de Strasbourg (IMS), ESBS 300 Boulevard S. Brant, 67400 Illkirch-Graffenstaden, France.

Neurobiology of Disease
|June 6, 2024
PubMed
Summary

A novel fluorinated apelin-13 peptide shows promise for multiple sclerosis (MS) treatment by preserving myelin and offering neuroprotection. This peptide may help manage MS by targeting neurodegeneration and inflammation.

Keywords:
Apelin-13Experimental autoimmune encephalomyelitisFluoropeptideMultiple sclerosis

More Related Videos

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

3.8K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

4.1K

Related Experiment Videos

Last Updated: Jun 24, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

3.8K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

4.1K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a neurodegenerative and autoimmune disease characterized by demyelination and axonal loss.
  • Current MS treatments focus on inflammation but lack neuroprotective capabilities.
  • Altered adipokine balance, specifically decreased apelin levels, is linked to MS risk and severity.

Purpose of the Study:

  • To investigate the neuroprotective potential of apelin in the context of MS.
  • To evaluate a novel, stabilized fluorinated apelin-13 peptide as a therapeutic agent for MS.

Main Methods:

  • Developed a fluorinated apelin-13 peptide with enhanced stability.
  • Administered the peptide in the experimental autoimmune encephalomyelitis (EAE) mouse model.
  • Assessed clinical scores, myelin preservation, and cellular functions (in vitro and ex vivo).

Main Results:

  • Apelin levels are significantly downregulated in the central nervous system (CNS) of EAE mice and MS patients.
  • Fluorinated apelin-13 peptide treatment ameliorated EAE clinical scores and preserved myelin.
  • Apelin demonstrated neuroprotective effects and modulated microglia/macrophage function.

Conclusions:

  • Apelin plays a crucial role in the CNS and its downregulation is associated with MS.
  • The novel fluorinated apelin-13 peptide is a promising therapeutic candidate for MS.
  • Apelin exhibits neuroprotective properties and influences immune cell function in the CNS.